Ryan Halsted
Stock Analyst at RBC Capital
(0.28)
# 4,386
Out of 5,146 analysts
8
Total ratings
25%
Success rate
-12.33%
Average return
Main Sectors:
Stocks Rated by Ryan Halsted
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDLN Medline | Maintains: Outperform | $47 → $53 | $50.59 | +4.76% | 2 | Feb 26, 2026 | |
| EVH Evolent Health | Maintains: Sector Perform | $5 → $3 | $3.22 | -6.83% | 1 | Feb 25, 2026 | |
| PRVA Privia Health Group | Reinstates: Outperform | $31 | $24.81 | +24.97% | 1 | Jan 9, 2026 | |
| TBRG TruBridge | Reinstates: Sector Perform | $23 | $20.36 | +12.97% | 1 | Jan 9, 2026 | |
| ENSG The Ensign Group | Downgrades: Underperform | n/a | $211.16 | - | 3 | Apr 28, 2017 |
Medline
Feb 26, 2026
Maintains: Outperform
Price Target: $47 → $53
Current: $50.59
Upside: +4.76%
Evolent Health
Feb 25, 2026
Maintains: Sector Perform
Price Target: $5 → $3
Current: $3.22
Upside: -6.83%
Privia Health Group
Jan 9, 2026
Reinstates: Outperform
Price Target: $31
Current: $24.81
Upside: +24.97%
TruBridge
Jan 9, 2026
Reinstates: Sector Perform
Price Target: $23
Current: $20.36
Upside: +12.97%
The Ensign Group
Apr 28, 2017
Downgrades: Underperform
Price Target: n/a
Current: $211.16
Upside: -